Opie's Cardiovascular Drugs: A Companion to Braunwald's Heart Disease PDF Download

Author: Deepak L. Bhatt
Publisher: Elsevier
ISBN: 9780323673617
Category : Medical
Languages : en
Pages : 720

View

Book Description
Authoritative, portable, and up to date, Opie's Cardiovascular Drugs, 9th Edition, is the definitive reference for quick access to frequently used drugs in all phases of care for cardiac patients. Now a part of the Braunwald family of renowned cardiology references, this compact title provides crucial information in an easily accessible format-ideal for cardiologists, residents, cardiology fellows, medical students, nurses, and other cardiac care providers. Updated to include the latest guidelines and evidence-based implications, it offers clear and concise explanations and pertinent clinical facts for all classes of cardiac drugs, as well as all the latest clinical trial results and evidence for the pharmacologic treatment of heart disease. Uses a new, consistent format for each drug class: overview and guidelines for use, mechanisms of action, differences among drugs in class, data for use, side effects, and drug interactions. Covers key topics such as new ESC and NLA guidelines, advances in lipid-lowering therapy, new diabetes drugs that improve cardiovascular outcomes, obesity drugs and cardiovascular and metabolic effects, drugs targeting inflammation, and combinations of antithrombotic therapies with analysis of risk-benefit. Provides guidance on how to effectively manage comorbid diseases. Contains dozens of unique "Opiegram" diagrams that demystify complex mechanisms of action and other drug processes-many updated to reflect current pathologic understanding of mechanisms. Enhanced eBook version included with purchase, which allows you to access all of the text, figures, and references from the book on a variety of devices

Author: William H. Frishman
Publisher: McGraw Hill Professional
ISBN: 9780071373630
Category : Medical
Languages : en
Pages : 820

View

Book Description
This manual, based on the definitive reference, is a concise and portable guide to the pharmacologic management of cardiovascular conditions. Focused on clinically relevant information related to drug treatment, this book features tables and charts for quick reference.

Author: William H. Frishman
Publisher: Springer Science & Business Media
ISBN: 146156767X
Category : Medical
Languages : en
Pages : 350

View

Book Description
The third edition of Current Cardiovascular Drugs is designed to provide an updated practical compendium of current knowledge regarding cardiovascular drug therapy in a concise, easily readable format. The book is organized into chapters by drug class, and details the pharmacologic characteristics of specific treatment entities. The clinical efficacy and limitations of the various drug therapies are discussed using supportive reference material from the most authoritative sources and published clinical trials.

Author: William H. Frishman
Publisher: Cardiotext Pub
ISBN: 9780979016431
Category : Medical
Languages : en
Pages : 775

View

Book Description
A critically acclaimed classic reference now in its third edition, Cardiovascular Pharmacotherapeutics provides current information regarding the contemporary use of all available cardiovascular medications for adults and children. Strongly emphasizing the scientific rationale behind the use of such therapies in cardiac disease, it discusses new drugs and novel compounds that are under development and may emerge as the cardiac therapies of the future. This edition also addresses special considerations for drug therapy use in the elderly, during pregnancy, and in those with hepatic or renal disease. A generous assortment of tables, figures, and appendices guides readers in their investigations of each drug group and various disease states.

Author: B. Rifkind
Publisher: CRC Press
ISBN: 9780824785123
Category : Medical
Languages : en
Pages : 296

View

Book Description
Originally published in 1991, ' Drugs Treatment of Hyperlipidemia' is a collection of essays that include studies on lipid metabolism, diagnosis of lipoprotein disorders, detection and treatment of dyslipoporteinemia and trials of lipid lowering drugs amongst its topics

Author: Antoni Martínez-Rubio
Publisher: Springer Nature
ISBN: 3030348938
Category : Medical
Languages : en
Pages : 433

View

Book Description
This volume reviews current and potential future therapies for arrhythmias. It is a highly practical guide for the use of pharmaceuticals in the management of the discipline, and has been written in a simple quick-access format. Antiarrhythmic Drugs builds on the current understanding of pathophysiological mechanisms and insights gained from previous studies of therapeutic interventions. It is designed to establish the baseline level of knowledge that a cardiovascular professional needs to know on a day-to-day basis.

Author: Stephan Gielen
Publisher: European Society of Cardiology
ISBN: 0199656657
Category : Medical
Languages : en
Pages : 369

View

Book Description
"EACPR, European Association for Cardiovascular Prevention and Rehabilitation -- European Society of Cardiology."

Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 030915698X
Category : Medical
Languages : en
Pages : 304

View

Book Description
The Social Security Administration (SSA) uses a screening tool called the Listing of Impairments to identify claimants who are so severely impaired that they cannot work at all and thus immediately qualify for benefits. In this report, the IOM makes several recommendations for improving SSA's capacity to determine disability benefits more quickly and efficiently using the Listings.

Author: Juan Carlos Kaski
Publisher:
ISBN: 0198759932
Category : Medical
Languages : en
Pages : 961

View

Book Description
The ESC Handbook on Cardiovascular Pharmacotherapy, based on the most recent guidelines in cardiovascular pharmacology, and containing a comprehensive A-Z formulary of common and less commonly used cardiac drugs and drug groups, provides practical and accessible guidance on all areas of drug prescribing.

Author: Institute of Medicine
Publisher: National Academies Press
ISBN: 0309212197
Category : Medical
Languages : en
Pages : 200

View

Book Description
Chronic diseases are common and costly, yet they are also among the most preventable health problems. Comprehensive and accurate disease surveillance systems are needed to implement successful efforts which will reduce the burden of chronic diseases on the U.S. population. A number of sources of surveillance data-including population surveys, cohort studies, disease registries, administrative health data, and vital statistics-contribute critical information about chronic disease. But no central surveillance system provides the information needed to analyze how chronic disease impacts the U.S. population, to identify public health priorities, or to track the progress of preventive efforts. A Nationwide Framework for Surveillance of Cardiovascular and Chronic Lung Diseases outlines a conceptual framework for building a national chronic disease surveillance system focused primarily on cardiovascular and chronic lung diseases. This system should be capable of providing data on disparities in incidence and prevalence of the diseases by race, ethnicity, socioeconomic status, and geographic region, along with data on disease risk factors, clinical care delivery, and functional health outcomes. This coordinated surveillance system is needed to integrate and expand existing information across the multiple levels of decision making in order to generate actionable, timely knowledge for a range of stakeholders at the local, state or regional, and national levels. The recommendations presented in A Nationwide Framework for Surveillance of Cardiovascular and Chronic Lung Diseases focus on data collection, resource allocation, monitoring activities, and implementation. The report also recommends that systems evolve along with new knowledge about emerging risk factors, advancing technologies, and new understanding of the basis for disease. This report will inform decision-making among federal health agencies, especially the Department of Health and Human Services; public health and clinical practitioners; non-governmental organizations; and policy makers, among others.